Orum Therapeutics Appoints Dr. Dorin Toader as Head of Platform Technology to Advance Orum's Degrader–Antibody Conjugate Payload Platforms and Expand TPD²® Therapeutic Applications [Yahoo!...
Mersana Therapeutics, Inc. (MRSN)
Last mersana therapeutics, inc. earnings: 2/28 06:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
mersana.com/about-mersana
Company Research
Source: Yahoo! Finance
the "Company") (KRX: 475830), a public biotechnology company pioneering the field of degrader-antibody conjugates (DACs), today announced the appointment of Dorin Toader, Ph.D., as Head of Platform Technology. Dr. Toader brings more than 27 years of experience in drug discovery, including over 15 years in antibody-drug conjugates (ADCs). He will be responsible for defining and executing Orum's technology vision, leading efforts across chemistry and antibody engineering, and guiding innovation in payload design, conjugation technologies, linker–payload strategies, structural biology, and computational modeling to advance Orum's Dual-Precision Targeted Protein Degradation (TPD²) approach and expand its therapeutic applications. "Dorin's career reflects a proven ability to translate bold science into clinical candidates, including advancing multiple first-in-class ADC candidates into the clinic," said Sung Joo (SJ) Lee, Founder and CEO of Orum. "His deep expertise in payload and linker
Show less
Read more
Impact Snapshot
Event Time:
MRSN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRSN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRSN alerts
High impacting Mersana Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
MRSN
News
- Mersana Therapeutics (NASDAQ:MRSN) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- How Mersana's Acquisition Is Changing the Story and Analyst Outlook for Investors [Yahoo! Finance]Yahoo! Finance
- Mersana Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Mersana Therapeutics, Inc. - MRSNBusiness Wire
- How the Acquisition Is Reshaping Mersana Therapeutics' Story and Analyst Outlook [Yahoo! Finance]Yahoo! Finance
- Mersana Therapeutics (NASDAQ:MRSN) was downgraded by analysts at Leerink Partnrs from a "strong-buy" rating to a "hold" rating.MarketBeat
MRSN
Earnings
- 11/14/25 - Miss
MRSN
Sec Filings
- 12/5/25 - Form SC
- 12/5/25 - Form SC
- 12/4/25 - Form SC
- MRSN's page on the SEC website